Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs

Introduction: Somatostatin analogs (SSAs) are used as part of standard treatment for advanced neuroendocrine tumors (NETs). The mechanisms behind the antiproliferative action of SSAs remain largely unknown, but a connection with the mammalian target of rapamycin (mTOR) signaling pathway has been sug...

ver descrição completa

Detalhes bibliográficos
Autor principal: Fernandes, Isabel (author)
Outros Autores: Pacheco, Teresa R. (author), Costa, Adília (author), Santos, Ana C. (author), Fernandes, Ana R. (author), Santos, Mara (author), Oliveira, António G. (author), Casimiro, Sandra (author), Quintela, António (author), Fernandes, Afonso (author), Ramos, Madalena (author), Costa, Luís (author)
Formato: article
Idioma:eng
Publicado em: 2017
Assuntos:
MTOR pathway
Neuroendocrine tumor
Somatostatin analogs
Oncology
Pharmacology (medical)
Texto completo:https://doi.org/10.2147/OTT.S36330
País:Portugal
Oai:oai:run.unl.pt:10362/24690

Texto Completo

https://doi.org/10.2147/OTT.S36330

Registros relacionados